Genetic Marker Clinical Trials
Led by Tracy Batchelor, MD, MPH at Massachusetts General Hospital/ Harvard Medical School
These Phase II trials will evaluate and monitor the genetic status of tumors in patients over time using biomarkers. Biomarkers have the potential to show which genetic changes in tumors make patients more responsive to a specific drug, whether genetic changes occur in the tumor during drug treatment, and how the patient responds to therapy.
Batchelor is a recent addition to VABC’s Medical Advisory Board.
Three of the four subsites for clinical trials have been opened and are currently enrolling patients in the study.
Click here for a full list of research grants funded by Voices Against Brain Cancer.